Cognition Therapeutics (CGTX) Accounts Payables (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Accounts Payables of $3.8 million for Q1 2026, up 111.42% year-over-year from $1.8 million in Q1 2025, and up 244.06% quarter-over-quarter from $1.1 million in Q4 2025.
Cognition Therapeutics (CGTX) Accounts Payables (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Accounts Payables for 7 consecutive years, with $3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 111.42% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (up 111.42% YoY), while the FY2025 annual figure was $1.1 million, down 43.6% from the prior year.
- Accounts Payables advanced to $3.8 million in Q1 2026 per CGTX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Accounts Payables topped out at $8.1 million in Q3 2022 and bottomed at $771000.0 in Q2 2025.
- Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 191.42% — and 2025, when it tumbled 74.59%.
- Cognition Therapeutics' Accounts Payables stood at $3.2 million in 2022, then increased by 14.89% to $3.7 million in 2023, then tumbled by 46.31% to $2.0 million in 2024, then sank by 43.6% to $1.1 million in 2025, then soared by 244.06% to $3.8 million in 2026.
- Business Quant data shows CGTX's Accounts Payables at $3.8 million in Q1 2026, $1.1 million in Q4 2025, and $827000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 673,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 673,000.00 |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 827,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 2.64 Mn |
| Dec 31, 2023 | 3.70 Mn |
| Sep 30, 2023 | 2.86 Mn |
| Jun 30, 2023 | 4.06 Mn |
| Mar 31, 2023 | 3.12 Mn |
| Dec 31, 2022 | 3.22 Mn |
| Sep 30, 2022 | 8.09 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | 4.17 Mn |
| Sep 30, 2021 | 2.78 Mn |